# Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

> **NCT01628588** · — · COMPLETED · sponsor: **Allergan** · enrollment: 854 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** bimatoprost 0.01%

## Key facts

- **NCT ID:** NCT01628588
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 854 (ACTUAL)
- **Last updated:** 2012-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01628588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01628588, "Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01628588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*